FACTOR XIII (FIBRIN STABILISING FACTOR) IN HENOCH‐SCHÖNLEIN'S PURPURA

Abstract. In 13 out of 17 consecutive children with Henoch‐Schönlein's purpura the factor XIII determined with the dansyl cadaverine method was found to be decreased during the acute phase. The decrease is assumed to be due to a specific degradation by proteolytic enzymes liberated from inflammatory cells, with defective local haemostasis as a result. This assumption is strengthened by the observation that treatment with factor XIII combined with an antifibrinolytic drug controlled life‐threatening gastro‐intestinal bleeding in one of the patients. It would therefore appear that such treatment might offer a new possibility of controlling severe haemorrhages in Henoch‐Schönlein's purpura.

[1]  P. Henriksson,et al.  Factor XIII in a clinical material. , 2009, Scandinavian journal of haematology.

[2]  P. Henriksson,et al.  Generalized proteolysis in a young woman with Weber-Christian disease (nodular nonsuppurative panniculitis). , 2009, Scandinavian journal of haematology.

[3]  I. Nilsson,et al.  Immunologic studies in haemophilia A. , 2009, Scandinavian journal of haematology.

[4]  M. Blombäck,et al.  On an inherited autosomal hemorrhagic diathesis with antihemophilic globulin (AHG) deficiency and prolonged bleeding time. , 2009, Acta medica Scandinavica.

[5]  I. Nilsson,et al.  Erosive Hemorrhagic Gastroduodenitis with Fibrinolysis and Low Factor XIII , 1975, Annals of surgery.

[6]  H. Roberts,et al.  Effect of lysosomal cationic proteins from polymorphonuclear leukocytes upon the fibrinogen and fibrinolysis system. , 1975, Thrombosis research.

[7]  K. Havemann,et al.  Effect of elastase-like and chymotrypsin-like neutral proteases from human granulocytes on isolated clotting factors. , 1975, Thrombosis research.

[8]  L. Lorand,et al.  Fibrin-stabilizing Factor (Factor XIII) in the Fetus and the Newborn Infant , 1974, Pediatric Research.

[9]  I. Nilsson,et al.  Antithrombin III in a clinical material , 1973 .

[10]  E. Ikkala.  TRANSFUSION THERAPY IN CONGENITAL DEFICIENCIES OF PLASMA FACTOR XIII , 1972, Annals of the New York Academy of Sciences.

[11]  F. Duckert.  DOCUMENTATION OF THE PLASMA FACTOR XIII DEFICIENCY IN MAN , 1972, Annals of the New York Academy of Sciences.

[12]  L. Lorand,et al.  Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. , 1969, The Journal of clinical investigation.

[13]  P. O. Ganrot,et al.  Immunochemical determination of human plasminogen. , 1968, Clinica chimica acta; international journal of clinical chemistry.

[14]  P. O. Ganrot.  Determination of α2-macroglobulin as trypsin-protein esterase , 1966 .

[15]  L. Lorand,et al.  Inhibitors of Fibrin Cross-linking : Relevance for Thrombolysis , 1966, Nature.

[16]  I. Nilsson,et al.  Determination of Fibrinogen and Fibrinogenolytic Activity , 1962, Thrombosis and Haemostasis.

[17]  L. Lorand,et al.  Accelerated Lysis of Blood Clots , 1962, Nature.

[18]  S. Björkman.  A new method for enumeration of platelets. , 1959 .

[19]  J. Gormsen,et al.  Plasmin digestion of stabilized and non-stabilized fibrin illustrated by pH-stat titration and thrombelastography. , 1971, Scandinavian journal of clinical and laboratory investigation.

[20]  P. Kierulf,et al.  Ethanol gelation and fibrin monomers in plasma. , 1971, Scandinavian journal of haematology. Supplementum.

[21]  J. Niléhn.  Separation and Estimation of Split “Products” of Fibrinogen and Fibrin in Human Serum , 1967, Thrombosis and Haemostasis.

[22]  I. Nilsson,et al.  A method for determining serum inhibitors of plasminogen activation. , 1962, Scandinavian journal of clinical and laboratory investigation.